Bio-Rad - Preparing for a Stress-free QC Audit

Medix Biochemica acquires Bioresource Technology

Medix Biochemica has acquired 100 percent of the shares of Bioresource Technology (BRT) to broaden its base matrix capabilities and further strengthen its local presence in the US market. As a result of this partnership, Medix Biochemica will provide its customers with a comprehensive offering of raw materials for their IVD quality control products. The organization and operations of BRT will form a significant part of Medix Biochemica’s IVD Biomaterials Business Unit, which also comprises manufacturing of native antigens, enzymes, proteins and biologicals in St. Louis, Missouri. BRT’s operations will stay in Weston, Florida, and BRT’s President Derik Reichenbach and CEO Ron Dilling will remain as strategic advisors following the acquisition.

Founded in 1984 by Dr. David Reichenbach, BRT is a leading provider of high-quality base matrices and other critical raw materials to many of the largest IVD manufacturers across the world.

“Together, we have the potential to broaden our offering to IVD companies across the globe. There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products. With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need,” said Steve Ferguson, CEO of Medix Biochemica.

Medix Biochemica